EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS

被引：0
|
作者：
Marzo-Ortega, Helena [1 ,2 ]
Meroni, Pierluigi [3 ]
Galindez-Agirregoikoa, Eva [4 ]
Behrens, Frank [5 ,6 ]
Bradley, Andrew J. [7 ]
Leage, Soyi Liu [7 ]
Garcia, Miriam [7 ]
Sapin, Christophe [7 ]
Ho, Ji Chen [8 ]
Constantin, Arnaud [9 ]
Hall, Stephen [10 ]
机构：
[1] Univ Leeds, Leeds Teaching Hosp Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[3] Univ Milan, Ist Auxol Italiano, Milan, Italy
[4] Univ Hosp Basurto, Serv Reumatol, Bilbao, Spain
[5] Goethe Univ Frankfurt, Div Rheumatol, Frankfurt, Germany
[6] Goethe Univ Frankfurt, IME Fraunhofer Project Grp Translat Med & Pharmac, Frankfurt, Germany
[7] Eli Lilly & Co, Lilly Int, Indianapolis, IN 46285 USA
[8] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[9] Hosp Pierre Paul Riquet, Dept Rheumatol, Toulouse, France
[10] Monash Univ, Dept Med, Clayton, Vic, Australia
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O03
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Smolen, J. S.
    Kavanaugh, A.
    Nash, P.
    Gallo, G.
    Leage, S. Liu
    Sapin, C.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698
  • [22] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    Bessette, Louis
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1167 - 1167
  • [24] 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)
    Mease, PJ
    Choy, EHS
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Weinberg, MA
    RHEUMATOLOGY, 2005, 44 : I3 - I3
  • [25] Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes
    Edwards, C. J.
    Bradley, A.
    Nassab, M. H.
    Moller, B.
    Machold, K. P.
    Sapin, C.
    Ranza, R.
    Liu-Leage, S.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
  • [26] IXEKIZUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES
    Chaudhury, Koyel
    Bradley, Andrew
    Nassab, Mani Haschemi
    Moeller, Burkhard
    Machold, Klaus P.
    Sapin, Christophe
    Ranza, Roberto
    Leage, Soyi Liu
    Nash, Peter
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 33 - 34
  • [27] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
    Mease, Philip J.
    Smolen, Josef S.
    Behrens, Frank
    Nash, Peter
    Leage, Soyi Liu
    Li, Lingnan
    Tahir, Hasan
    Gooderham, Melinda
    Krishnan, Eswar
    Liu-Seifert, Hong
    Emery, Paul
    Pillai, Sreekumar G.
    Helliwell, Philip S.
    Naftal, Leonardo
    Hidalgo, Rodolfo Ariel Pardo
    Kerzberg, Eduardo Mario
    Savio, Veronica Gabriela
    Lazaro, Alicia
    Velasco, Benito Jorge
    Verzero, Norma Beatriz
    Asnal, Cecilia Adma
    Mysler, Eduardo Fabian
    Berman, Alberto
    Ariel, Federico Javier
    Rischmueller, Maureen
    Zochling, Jane Margaret
    Bird, Paul A.
    Hall, Stephen
    Ostor, Andrew
    Romas, Evange
    Stummvoll, Georg
    Machold, Klaus
    Spellitz, Peter
    Hanusch, Ursula
    Vanden Berghe, Marc
    Leon, Marc
    Vanhoof, Johan Louis Magda
    Van den Bosch, Filip Eduard Jeanne
    De Vlam, Kurt Leo Francois
    Morin, Frederic
    Bessette, Louis
    Haaland, Derek A.
    Schlemmer, Annette Margrethe
    Kristensen, Lars Erik
    Jarvinen, Pentti
    Peltomaa, Ritva Liisa
    Pirila, Laura
    Vuotila, Jorma
    Lespessailles, Eric
    Goupille, Philippe
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 123 - 131
  • [28] Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
    Gottlieb, Alice B.
    Coates, Laura C.
    Shuler, Catherine L.
    Lin, Chen-Yen
    Moriarty, Susan R.
    Lee, Chin H.
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] EFFECT OF CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARDS) ON THE EFFICACY AND SAFETY OF IXEKIZUMAB IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Coates, L. C.
    Gottlieb, A. B.
    Shuler, C. L.
    Lin, C-Y
    Samanta, S.
    Moriarty, S. R.
    Lee, C. H.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 350 - 351
  • [30] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 23 - 24
12345